ROYALTY INTEREST PURCHASE AGREEMENTRoyalty Interest Purchase Agreement • December 29th, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations • Utah
THIS ROYALTY INTEREST PURCHASE AGREEMENT (this “Agreement”), dated as of December 22, 2020, is entered into by and between JAGUAR HEALTH, INC., a Delaware corporation (“Company”), and IRVING PARK CAPITAL, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”).
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream No royalty payments due for 18-24 monthsRoyalty Financing Agreement • December 29th, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations
San Francisco, CA (December 23, 2020): Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today announced that the Company has signed an agreement (the “Agreement”) with a secured lender (the “Lender”) for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $6 million (the “Royalty Purchase Price”) a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties of Mytesi® (crofelemer) and lechlemer and certain up-front license fees and milestone payments from licensees and/or distributors as well as any interest, fees, and charges in accordance with the terms set forth in the Agreement (the “Royalty Repayment Amount”), and to pay interest on the Royalty Repayment Amount at the rate of ten percent per annum until the same is paid in full.
